Deryk T. Loo
Bristol-Myers Squibb
41 Papers
219 Citations
Deryk T. Loo is an academic researcher from Bristol-Myers Squibb. The author has contributed to research in topics: Cancer & Monoclonal antibody. The author has an hindex of 13, co-authored 36 publications.
Chat about Author
Papers
Development of an Fc-Enhanced Anti–B7-H3 Monoclonal Antibody with Potent Antitumor Activity
Deryk T. Loo,Ralph Alderson,Francine Chen,Ling Huang,Wenjun Zhang,Sergey Gorlatov,Steve Burke,Valentina Ciccarone,Hua Li,Yinhua Yang,Tom Son,Y Chen,Ann Easton,Jonathan C. Li,Jill Rillema,Monica Licea,Claudia B. Fieger,Tony W. Liang,Jennie P. Mather,Scott Koenig,Stanford J. Stewart,Syd Johnson,Ezio Bonvini,Paul A. Moore +23 more
TL;DR: Evaluation of MGA271 clinical utility in B7-H3–expressing cancer is supported, while validating a combination of a nontarget biased approach of intact cell immunizations and immunohistochemistry to identify novel cancer antigens with Fc-based mAb engineering to enable potent antitumor activity.
284
Measurement of cell death
Deryk T. Loo,Jill Rillema +1 more
TL;DR: The use of one or more of the methods described in this chapter for measuring cell death should enable investigators to accurately assess apoptosis in the context of the various models being examined and help define causal relationships between the mechanisms that regulate apoptosis and the cell death event itself.
234
Patent
Antibodies Reactive with B7-H3 and Uses Thereof
Leslie S. Johnson,Ling Huang,Paul A. Moore,Deryk T. Loo,Francine Chen +4 more
- 04 May 2012
TL;DR: In this paper, the human B7-H3 receptor is used to mediate mediating, and more preferably enhancing the activation of the immune system against cancer cells that are associated with a variety of human cancers.
48
Analysis of 4-1BBL and Laminin Binding to Murine 4-1BB, a Member of the Tumor Necrosis Factor Receptor Superfamily, and Comparison with Human 4-1BB *
Deryk T. Loo,N. Jan Chalupny,Jürgen Bajorath,Walter W. Shuford,Robert S. Mittler,Alejandro Aruffo +5 more
TL;DR: It is reported that binding of m4-1BBL to m 4-1BB blocked its ability to bind laminin (LN), while binding ofm4- 1BB to LN did not block its able to bind m4’s 1BBL, and these findings suggest the two ligands bind to proximal but distinct sites on m4,1BB.
40
Phase 1 dose escalation study of MGC018, an anti-B7-H3 antibody-drug conjugate (ADC), in patients with advanced solid tumors.
Sekwon Jang,John D. Powderly,Alexander I. Spira,Ouiam Bakkacha,Deryk T. Loo,Gerry C. Bohac,Manish Sharma +6 more
TL;DR: A phase 1 study characterizes safety, maximum tolerated or maximum administered dose, pharmacokinetics, immunogenicity, and tumor response per RECIST v1.1 of MGC018 in patients with advanced solid tumors, with early evidence of clinical activity in pretreated metastatic melanoma.
29